Genzyme’s current expectation is that it will be able to resume shipments of Thyrogen® in the United States during the week of June 20th. Genzyme notifed U.S. health care providers today of this anticipated timing so that individual patient treatments could be scheduled appropriately. Genzyme qualified the notice as a “best estimate of anticipated resumption of U.S. Thyrogen® supply” and stated that the inventory is extremely limited so that even minor changes to their current manufacturing plan can impact the timing of Thyrogen® availability.